Endometrial Cancer Trial, Recruiting NCT07318727 Sponsor: Peking University People's Hospital Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT07318727
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older
  • People who have been diagnosed with endometrial cancer or a condition called atypical hyperplasia (an abnormal growth of cells in the lining of the uterus)
  • People who are undergoing fertility-preserving treatment (treatment that aims to protect the ability to have children)
  • People with a Body Mass Index (BMI) of 25 or higher (a measure of body weight relative to height)
  • People who have given their informed consent to participate

Who may not be able to join:

  • People who have difficulty communicating (confirm with trial site)
  • People who are currently pregnant
  • People with certain serious medical conditions, including kidney stones, a history of kidney failure or severe kidney problems, an inherited condition affecting cholesterol or fats in the blood, severe liver disease, a long-term condition affecting the body's acid balance, a history of pancreas inflammation, severe diabetes, active gallbladder disease, difficulty digesting fats, or serious heart or blood vessel conditions affecting the heart or brain

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Li Xiaodan, Master, Peking University People's Hospital

Phone: 15010305099

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Peking University People's Hospital
Registry
ClinicalTrials.gov
Start date
10 January 2025
Est. completion
31 March 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Body Mass Index(BMI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov